{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T15:39:37Z","timestamp":1793547577888,"version":"4.5.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,15]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>To systematically review the efficacy and safety of second-line medications for status epilepticus (SE).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Electronic searches were conducted in PubMed, Embase, and The Cochrane Library for randomized controlled trials of second-line medications for SE from inception to January 2024. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of included studies. Network meta-analysis was performed using R 4.2.2 software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 23 randomized controlled trials were analyzed, examining the efficacy of 5 different treatment regimens: levetiracetam (LEV), phenytoin (PHT), fosphenytoin (FPHT), valproate (VPA), and phenobarbital (PHB). The results of the network meta-analysis indicated that the seizure control rate ranking was as follows: PHB (98.1%)\u2005&gt;\u2005LEV (60.7%)\u2005&gt;\u2005FPHT (40.3%)\u2005&gt;\u2005PHT (33.0%)\u2005&gt;\u2005VPA (17.8%). The surface under the cumulative ranking (SUCRA) values revealed that PHB had the highest ranking (SUCRA, 91.8%), followed by VPA (SUCRA, 69.3%), PHT (SUCRA, 56.1%), and FPHT (SUCRA, 5.9%) for the recurrence of seizures within 24\u2005hours. Subgroup analysis revealed that PHB was most effective for seizure control in both pediatric and adult populations, VPA demonstrated superior efficacy in children across various indicators, LEV was deemed the safest option for children and elderly individuals, and VPA was identified as the safest choice for adult patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>PHB continues to be a prominent option for managing SE, although its safety profile warrants careful consideration. Meanwhile, both VPA and LEV offer distinctive advantages in the treatment of SE, with each demonstrating commendable safety profiles.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040333","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:06:51Z","timestamp":1732032411000},"page":"e40333","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Comparative efficacy and safety of second-line medications for status epilepticus: A network meta-analysis"],"prefix":"10.1097","volume":"103","author":[{"given":"Qishun","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Neurology, Huaihe Hospital of Henan University, Kaifeng, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaokang","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huaihe Hospital of Henan University, Kaifeng, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huaihe Hospital of Henan University, Kaifeng, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8984-524X","authenticated-orcid":false,"given":"Xiangshu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huaihe Hospital of Henan University, Kaifeng, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","DOI":"10.1097\/MCC.0000000000001137","article-title":"Status epilepticus: what\u2019s new for the intensivist.","author":"Benghanem","year":"2024","journal-title":"Curr Opin Crit Care"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000533191","article-title":"Management of status epilepticus by different pediatric departments: neurology, intensive care, and emergency medicine.","volume":"86","author":"Dedeoglu","year":"2023","journal-title":"Eur Neurol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"e13380","DOI":"10.1016\/j.heliyon.2023.e13380","article-title":"Efficacy and safety of levetiracetam versus valproate in patients with established status epilepticus: a systematic review and meta-analysis.","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"109093","DOI":"10.1016\/j.yebeh.2023.109093","article-title":"Treatment of benzodiazepine-refractory status epilepticus: a retrospective, cohort study.","volume":"140","author":"Rollo","year":"2023","journal-title":"Epilepsy Behav"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"107964","DOI":"10.1016\/j.yebeh.2021.107964","article-title":"Efficacy of oral perampanel in status epilepticus and acute repetitive seizures in children at a tertiary care hospital in Thailand.","volume":"118","author":"Wachiropathum","year":"2021","journal-title":"Epilepsy Behav"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s12883-020-02001-x","article-title":"Treatment of established status epilepticus in the elderly - a study protocol for a prospective multicenter double-blind comparative effectiveness trial (ToSEE).","volume":"20","author":"M\u00fcller","year":"2020","journal-title":"BMC Neurol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s40263-022-00940-2","article-title":"Benzodiazepines in the management of seizures and status epilepticus: a review of routes of delivery, pharmacokinetics, efficacy, and tolerability.","volume":"36","author":"Kienitz","year":"2022","journal-title":"CNS Drugs"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/ene.13560","article-title":"A critical appraisal of randomized controlled trials on intravenous phenytoin in convulsive status epilepticus.","volume":"25","author":"Brigo","year":"2018","journal-title":"Eur J Neurol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"109104","DOI":"10.1016\/j.yebeh.2023.109104","article-title":"Phenobarbital in Status epilepticus - Rediscovery of an effective drug.","volume":"141","author":"Trinka","year":"2023","journal-title":"Epilepsy Behav"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.seizure.2022.09.017","article-title":"Treatment of benzodiazepine-resistant status epilepticus: systematic review and network meta-analyses.","volume":"102","author":"Jain","year":"2022","journal-title":"Seizure"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1056\/NEJM199809173391202","article-title":"A comparison of four treatments for generalized convulsive status epilepticus. Veterans affairs status epilepticus cooperative study group.","volume":"339","author":"Treiman","year":"1998","journal-title":"N Engl J Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.seizure.2007.04.012","article-title":"Randomized study of intravenous valproate and phenytoin in status epilepticus.","volume":"16","author":"Agarwal","year":"2007","journal-title":"Seizure"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"e00951","DOI":"10.1002\/brb3.951","article-title":"Sodium valproate compared to phenytoin in treatment of status epilepticus.","volume":"8","author":"Amiri-Nikpour","year":"2018","journal-title":"Brain Behav"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3389\/fneur.2019.00506","article-title":"A Comparison of parenteral phenobarbital vs. parenteral phenytoin as second-line management for pediatric convulsive status epilepticus in a resource-limited setting.","volume":"10","author":"Burman","year":"2019","journal-title":"Front Neurol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jocn.2014.12.013","article-title":"Levetiracetam versus phenytoin in management of status epilepticus.","volume":"22","author":"Chakravarthi","year":"2015","journal-title":"J Clin Neurosci"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0140-6736(20)30611-5","article-title":"Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.","volume":"395","author":"Chamberlain","year":"2020","journal-title":"Lancet"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/S0140-6736(19)30722-6","article-title":"Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial.","volume":"393","author":"Dalziel","year":"2019","journal-title":"Lancet"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.seizure.2017.05.001","article-title":"Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: a prospective, randomized study.","volume":"49","author":"Gujjar","year":"2017","journal-title":"Seizure"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4103\/jpn.JPN_109_19","article-title":"Levetiracetam versus fosphenytoin in pediatric convulsive status epilepticus: a randomized controlled trial.","volume":"15","author":"Handral","year":"2020","journal-title":"J Pediatr Neurosci"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","article-title":"Randomized trial of three anticonvulsant medications for status epilepticus.","volume":"381","author":"Kapur","year":"2019","journal-title":"N Engl J Med"},{"key":"R21-20250504","first-page":"85","article-title":"Comparison of the effect of phenobarbital versus sodium valproate in management of children with status epilepticus.","volume":"12","author":"Khajeh","year":"2018","journal-title":"Iran J Child Neurol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(19)30724-X","article-title":"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.","volume":"393","author":"Lyttle","year":"2019","journal-title":"Lancet"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejpn.2012.01.012","article-title":"Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial.","volume":"16","author":"Malamiri","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1212\/01.wnl.0000224880.35053.26","article-title":"Sodium valproate vs phenytoin in status epilepticus: a pilot study.","volume":"67","author":"Misra","year":"2006","journal-title":"Neurology"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.04.013","article-title":"Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam--Pilot study.","volume":"114","author":"Mundlamuri","year":"2015","journal-title":"Epilepsy Res"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12098-020-03221-2","article-title":"Clinical effectiveness of levetiracetam compared to fosphenytoin in the treatment of benzodiazepine refractory convulsive status epilepticus.","volume":"87","author":"Nalisetty","year":"2020","journal-title":"Indian J Pediatr"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"69","DOI":"10.14581\/jer.20011","article-title":"Comparative Efficacy of IV Phenytoin, IV Valproate, and IV Levetiracetam in Childhood Status Epilepticus.","volume":"10","author":"Nazir","year":"2020","journal-title":"J Epilepsy Res"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.seizure.2019.01.015","article-title":"Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): a prospective randomized controlled pilot study.","volume":"65","author":"Nene","year":"2019","journal-title":"Seizure"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3988\/jcn.2019.15.4.468","article-title":"Clinical efficacy and safety of injectable levetiracetam versus phenytoin as second-line therapy in the management of generalized convulsive status epilepticus in children: an open-label randomized controlled trial.","volume":"15","author":"Noureen","year":"2019","journal-title":"J Clin Neurol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4103\/JPN.JPN_126_17","article-title":"IV Levetiracetam versus IV phenytoin in childhood seizures: a randomized controlled trial.","volume":"13","author":"Singh","year":"2018","journal-title":"J Pediatr Neurosci"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40263-016-0388-6","article-title":"Phenobarbital versus valproate for generalized convulsive status epilepticus in adults: a prospective randomized controlled trial in China.","volume":"30","author":"Su","year":"2016","journal-title":"CNS Drugs"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s13312-020-1755-4","article-title":"Comparison of phenytoin, valproate and levetiracetam in pediatric convulsive status epilepticus: a randomized double-blind controlled clinical trial.","volume":"57","author":"Vignesh","year":"2020","journal-title":"Indian Pediatr"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.4103\/jfmpc.jfmpc_750_19","article-title":"Levetiracetam versus phenytoin in children with status epilepticus.","volume":"8","author":"Wani","year":"2019","journal-title":"J Family Med Prim Care"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"237","DOI":"10.17511\/ijpr.2018.i04.13","article-title":"Randomized controlled trial of levetiracetam versus fosphenytoin for convulsive status epilepticus in children.","volume":"5","author":"Senthilkumar","year":"2018","journal-title":"Int J Pediatr Res"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.seizure.2020.05.017","article-title":"Phenytoin versus fosphenytoin for second-line treatment of status epilepticus: propensity score matching analysis using a nationwide inpatient database.","volume":"80","author":"Nakamura","year":"2020","journal-title":"Seizure"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"106466","DOI":"10.1016\/j.yebeh.2019.106466","article-title":"Intravenous antiepileptic drugs in adults with benzodiazepine-resistant convulsive status epilepticus: a systematic review and network meta-analysis.","volume":"101","author":"Brigo","year":"2019","journal-title":"Epilepsy Behav"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:04:05Z","timestamp":1746320645000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":36,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040333","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}